AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12548256 — intervention group
Group type: COMPARATOR
Intervention: No use of aloe vera gel gloves (control)
Number of subjects: 29
Study 11129359 — intervention group
Group type: EXPERIMENTAL
Intervention: Baby contact (holding baby) during laboratory stress assessment
Number of subjects: 25
Study 11129359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin increase group (mothers with increased plasma OT after baby contact)
Number of subjects: 25
Study 11129359 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin decrease group (mothers with decreased plasma OT after baby contact)
Number of subjects: 25
Study 11129359 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast-feeding mothers (OT increase group)
Number of subjects: 25
Study 11129359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle-feeding mothers (OT decrease group)
Number of subjects: 25
Study 8695134 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane anesthesia with mivacurium infusion
Number of subjects: 41
Study 8695134 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane anesthesia with mivacurium infusion
Number of subjects: 41
Study 8695134 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Desflurane and Isoflurane)
Number of subjects: 41
Study 1627030 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol level measured at initial screening
Number of subjects: 350977
Study 1627030 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol level less than 4.14 mmol/L (less than 160 mg/dL)
Number of subjects: 350977
Study 1627030 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum cholesterol level
Number of subjects: 350977
Study 6439955 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental behavioral program
Number of subjects: 0
Study 6439955 — intervention group
Group type: COMPARATOR
Intervention: Control group (no behavioral strategies)
Number of subjects: 0
Study 31476159 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI levels
Number of subjects: 160
Study 31476159 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse metabolic biomarker profiles
Number of subjects: 160
Study 31476159 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 160
Study 28318850 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperosmolar irrigation solution (593 mOsm/L)
Number of subjects: 50
Study 28318850 — intervention group
Group type: COMPARATOR
Intervention: Isotonic irrigation solution (273 mOsm/L)
Number of subjects: 50
Study 26828770 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually delivered cognitive behavioral therapy (n = 62)
Number of subjects: 146
Study 26828770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy (n = 61)
Number of subjects: 146
Study 26828770 — intervention group
Group type: COMPARATOR
Intervention: Group-delivered integrated cognitive behavioral therapy
Number of subjects: 146
Study 26828770 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive processing therapy
Number of subjects: 146
Study 25028274 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sulfate solution (OSS)
Number of subjects: 338
Study 25028274 — intervention group
Group type: COMPARATOR
Intervention: Sodium picosulfate plus magnesium citrate (SP+MC)
Number of subjects: 338
Study 22389080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependent individuals exposed to stress imagery
Number of subjects: 28
Study 22389080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependent individuals at baseline
Number of subjects: 28
Study 22389080 — intervention group
Group type: COMPARATOR
Intervention: Social drinkers exposed to drug cue imagery
Number of subjects: 28
Study 22389080 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine dependent individuals exposed to relaxing imagery
Number of subjects: 28
Study 18586273 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone (0.5-3mg/day)
Number of subjects: 97
Study 18586273 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 97
Study 18586273 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 97
Study 17596576 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 17313
Study 17596576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17313
Study 15669590 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbotomic access
Number of subjects: 94
Study 15669590 — intervention group
Group type: COMPARATOR
Intervention: Laparotomic access
Number of subjects: 94
Study 12453549 — intervention group
Group type: EXPERIMENTAL
Intervention: General practitioners' management of patients with heart failure based on symptoms and signs alone.
Number of subjects: 18
Study 12453549 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest X-ray and electrocardiogram arrangements for diagnosis.
Number of subjects: 18
Study 12453549 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial of diuretics for diagnosis.
Number of subjects: 18
Study 12453549 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstacles to diagnosis and management of heart failure.
Number of subjects: 18
Study 12453549 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the impact of angiotensin‐converting enzyme inhibitors.
Number of subjects: 18
Study 11289568 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg vardenafil
Number of subjects: 21
Study 11289568 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil
Number of subjects: 21
Study 11289568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9165135 — intervention group
Group type: EXPERIMENTAL
Intervention: 66 Gy in 33 2 Gy twice daily fractions in 22-25 days (b.i.d.)
Number of subjects: 82
Study 9165135 — intervention group
Group type: COMPARATOR
Intervention: 66 Gy in 33 2 Gy daily fractions in 45-48 days (o.d.)
Number of subjects: 82
Study 11767423 — intervention group
Group type: EXPERIMENTAL
Intervention: Affirmative and non-affirmative suggestions
Number of subjects: 82
Study 11767423 — intervention group
Group type: COMPARATOR
Intervention: Affirmative suggestions
Number of subjects: 82
Study 11767423 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmative suggestions
Number of subjects: 82
Study 11767423 — intervention group
Group type: COMPARATOR
Intervention: Irrelevant text
Number of subjects: 82
Study 3119481 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard solution containing crystalline amino acids (3.8 g/l), xylitol (25 g/l) and sorbitol (25 g/l), accounting for a total of 900 cal/day
Number of subjects: 31
Study 3119481 — intervention group
Group type: COMPARATOR
Intervention: Water, electrolytes and glucose
Number of subjects: 31
Study 29316945 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing visit on appropriate prescribing of pain relief medication
Number of subjects: 3529
Study 29316945 — intervention group
Group type: COMPARATOR
Intervention: Control group (no academic detailing visit)
Number of subjects: 3529
Study 27517163 — intervention group
Group type: EXPERIMENTAL
Intervention: Same-admission cholecystectomy
Number of subjects: 264
Study 27517163 — intervention group
Group type: COMPARATOR
Intervention: Interval cholecystectomy
Number of subjects: 264
Study 24746411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulverized brand-name and generic drugs containing amlodipine (Norvasc(®), Amlodipin‐Mepha(®), Amlodipin Pfizer(®))
Number of subjects: 31
Study 24746411 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulverized brand-name and generic drugs containing candesartan (Atacand(®), Cansartan‐Mepha(®), Pemzek(®))
Number of subjects: 31
Study 23570051 — intervention group
Group type: EXPERIMENTAL
Intervention: 2010-2011 non-adjuvanted TIV (Fluviral®, GSK Canada)
Number of subjects: 326
Study 23570051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 19838801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic meditation (CM)
Number of subjects: 30
Study 19838801 — intervention group
Group type: COMPARATOR
Intervention: Supine rest (SR)
Number of subjects: 30
Study 18785556 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft group (enriched bone marrow mesenchymal stem cells hybridized with beta‐tri calcium phosphate)
Number of subjects: 56
Study 18785556 — intervention group
Group type: COMPARATOR
Intervention: Autograft group (autologous iliac crest bone graft)
Number of subjects: 56
Study 18785556 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft group
Number of subjects: 56
Study 18785556 — intervention group
Group type: COMPARATOR
Intervention: Autograft group
Number of subjects: 56
Study 18785556 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 56
Study 16841035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractionated PDT (2-fold illumination scheme with two light fractions of 20 and 80 J cm(‐2))
Number of subjects: 154
Study 16841035 — intervention group
Group type: COMPARATOR
Intervention: Single illumination (75 J cm(‐2))
Number of subjects: 154
Study 14706729 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative monotherapy
Number of subjects: 157
Study 14706729 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive therapy
Number of subjects: 157
Study 10803803 — intervention group
Group type: EXPERIMENTAL
Intervention: L-acetylcarnitine
Number of subjects: 24
Study 10803803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8641911 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy consisting of prophylactic hepatic irradiation and pancreatic bed irradiation with concurrent infusional 5‐fluorouracil (200 mg/m2/day) and leucovorin (5 mg/m2/day) for 5 out of every 7 days during the 38‐day treatment sequence.
Number of subjects: 14
Study 1555461 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 percent O2
Number of subjects: 15
Study 1555461 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 15
Study 31986997 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher resilience
Number of subjects: 105
Study 29801061 — intervention group
Group type: EXPERIMENTAL
Intervention: MC1R test offer
Number of subjects: 499
Study 29801061 — intervention group
Group type: COMPARATOR
Intervention: Usual-care condition (National Cancer Institute skin cancer pamphlet)
Number of subjects: 499
Study 27590876 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructose feeding
Number of subjects: 20
Study 27590876 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose feeding
Number of subjects: 20
Study 25245353 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR AM + psychostimulant
Number of subjects: 461
Study 25245353 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR PM + psychostimulant
Number of subjects: 461
Study 25245353 — intervention group
Group type: COMPARATOR
Intervention: Placebo + psychostimulant
Number of subjects: 461
Study 22646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct correlation small group sessions
Number of subjects: 0
Study 22646297 — intervention group
Group type: COMPARATOR
Intervention: Control method (identical laboratory and teaching conditions without simultaneous correlation)
Number of subjects: 0
Study 22646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Cross-over group preference
Number of subjects: 0
Study 22646297 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation teaching sessions
Number of subjects: 0
Study 19892408 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.5mg/kg 15s post-stimulus
Number of subjects: 15
Study 19892408 — intervention group
Group type: COMPARATOR
Intervention: No propofol
Number of subjects: 15
Study 18277843 — intervention group
Group type: EXPERIMENTAL
Intervention: Transillumination using Veinlite
Number of subjects: 240
Study 18277843 — intervention group
Group type: COMPARATOR
Intervention: Nontransillumination (control group)
Number of subjects: 240
Study 16489968 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart (BIAsp)
Number of subjects: 167
Study 16489968 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 167
Study 14609904 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with symptoms consistent with nonspecific functional abdominal pain
Number of subjects: 0
Study 14609904 — intervention group
Group type: COMPARATOR
Intervention: Children with symptoms of irritable bowel syndrome or functional dyspepsia
Number of subjects: 0
Study 10841227 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACEi)
Number of subjects: 96712
Study 10841227 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 96712
Study 9443518 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg diazepam
Number of subjects: 12
Study 9443518 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg oxazepam
Number of subjects: 12
Study 9443518 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone
Number of subjects: 12
Study 9443518 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg zolpidem
Number of subjects: 12
Study 9443518 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.65+0.35 g/kg ethanol
Number of subjects: 12
Study 9443518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8450161 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy
Number of subjects: 148
Study 3777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (12 sessions of 10-min each)
Number of subjects: 20
Study 3777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (6 sessions of 20-min each)
Number of subjects: 20
Study 3777111 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (3 sessions of 40-min each)
Number of subjects: 20
Study 3777111 — intervention group
Group type: COMPARATOR
Intervention: Group D (control group)
Number of subjects: 20
Study 30572906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Number of subjects: 0
Study 30572906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26967896 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylcholine (0.8 mg/kg)
Number of subjects: 45
Study 26967896 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium (0.4 mg/kg)
Number of subjects: 45
Study 25012985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate 150, 250, 350, or 500 mg tid
Number of subjects: 23
Study 25012985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate 500 mg tid
Number of subjects: 23
Study 25012985 — intervention group
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Number of subjects: 23
Study 25012985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22660484 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivascular ultrasound-guided axillary brachial plexus block
Number of subjects: 50
Study 22660484 — intervention group
Group type: COMPARATOR
Intervention: Perineural ultrasound-guided axillary brachial plexus block
Number of subjects: 50
Study 20441134 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiencing role as player
Number of subjects: 0
Study 20441134 — intervention group
Group type: COMPARATOR
Intervention: Experiencing role as spectator
Number of subjects: 0
Study 18546285 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) 20-190 units
Number of subjects: 29
Study 18546285 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 18546285 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 29
Study 15753790 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET imaging at 2 hours
Number of subjects: 12
Study 15753790 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET imaging at 3 hours
Number of subjects: 12
Study 15753790 — intervention group
Group type: COMPARATOR
Intervention: 18F-FDG-PET imaging at 1 hour
Number of subjects: 12
Study 12434942 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT+MI
Number of subjects: 53
Study 12434942 — intervention group
Group type: EXPERIMENTAL
Intervention: SCT-only
Number of subjects: 53
Study 12434942 — intervention group
Group type: COMPARATOR
Intervention: Education-only
Number of subjects: 53
Study 10367620 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD-positive veterans
Number of subjects: 286
Study 10367620 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety disorders
Number of subjects: 286
Study 10367620 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed veterans
Number of subjects: 286
Study 7724298 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose-based oral rehydration solution (Pedialyte)
Number of subjects: 60
Study 7724298 — intervention group
Group type: COMPARATOR
Intervention: Rice syrup solids-based ORS (Infalyte)
Number of subjects: 60
Study 2029011 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 20
Study 2029011 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg
Number of subjects: 20
Study 2029011 — intervention group
Group type: COMPARATOR
Intervention: Control (Group A)
Number of subjects: 20
Study 7273791 — intervention group
Group type: EXPERIMENTAL
Intervention: Five-drug combination chemotherapy
Number of subjects: 0
Study 7273791 — intervention group
Group type: COMPARATOR
Intervention: Single agent sequential treatment
Number of subjects: 0
Study 28965435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopuff (early continuous positive airway pressure via T-piece-based infant resuscitator) for 20 minutes
Number of subjects: 64
Study 28965435 — intervention group
Group type: COMPARATOR
Intervention: Free flow O2 (control group)
Number of subjects: 64
Study 28965435 — intervention group
Group type: EXPERIMENTAL
Intervention: Neopuff
Number of subjects: 64
Study 28207264 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated approach to detect and cure incorrect orbital convergence
Number of subjects: 0
Study 24792011 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal mesh repair
Number of subjects: 60
Study 24792011 — intervention group
Group type: COMPARATOR
Intervention: Preaponeurotic mesh repair
Number of subjects: 60
Study 24260764 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdosteine only
Number of subjects: 0
Study 24260764 — intervention group
Group type: COMPARATOR
Intervention: Combination of erdosteine and nasal corticosteroid spray
Number of subjects: 0
Study 21288804 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose of IXIARO (IC51) administered 15 months after primary immunization.
Number of subjects: 198
Study 19595518 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (up to 300 mg/day)
Number of subjects: 155
Study 19595518 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 mg/day)
Number of subjects: 155
Study 19595518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 16458598 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h nicotine patch
Number of subjects: 20
Study 16458598 — intervention group
Group type: COMPARATOR
Intervention: 16-h nicotine patch
Number of subjects: 20
Study 12549956 — intervention group
Group type: EXPERIMENTAL
Intervention: Desloratadine (once-daily treatment)
Number of subjects: 0
Study 12549956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10965735 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg oral dexketoprofen
Number of subjects: 45
Study 10965735 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg oral ketoprofen
Number of subjects: 45
Study 10965735 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral paracetamol
Number of subjects: 45
Study 10965735 — intervention group
Group type: COMPARATOR
Intervention: Rescue tramadol
Number of subjects: 45
Study 10965735 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall pain relief
Number of subjects: 45
Study 9005368 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day per os
Number of subjects: 30
Study 9005368 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate 3.75 mg monthly intramuscularly
Number of subjects: 30
Study 1453211 — intervention group
Group type: EXPERIMENTAL
Intervention: 32-mg single dose of ondansetron
Number of subjects: 699
Study 1453211 — intervention group
Group type: COMPARATOR
Intervention: 8-mg single dose of ondansetron
Number of subjects: 699
Study 1453211 — intervention group
Group type: COMPARATOR
Intervention: 0.15 mg/kg times three doses of ondansetron
Number of subjects: 699
Study 3893704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (400 mg/4 ml)
Number of subjects: 34
Study 3893704 — intervention group
Group type: COMPARATOR
Intervention: Noramidopyrine (1 gm/2 ml)
Number of subjects: 34
Study 3893704 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen
Number of subjects: 34
Study 3893704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both NSAIDs
Number of subjects: 34
Study 31357916 — intervention group
Group type: EXPERIMENTAL
Intervention: BA+exercise
Number of subjects: 31
Study 31357916 — intervention group
Group type: COMPARATOR
Intervention: BA+stretching
Number of subjects: 31
Study 31357916 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BA+exercise and BA+stretching)
Number of subjects: 31
Study 31357916 — intervention group
Group type: EXPERIMENTAL
Intervention: More exercise engagement
Number of subjects: 31
Study 28386808 — intervention group
Group type: EXPERIMENTAL
Intervention: The Mindfulness‐Enhanced Strengthening Families Program 10‐14 (MSFP 10‐14)
Number of subjects: 515
Study 28386808 — intervention group
Group type: COMPARATOR
Intervention: The Strengthening Families Program: For Parents and Youth 10‐14 (SFP 10‐14)
Number of subjects: 515
Study 26332107 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG‐gated 64‐slice multidetector computed tomography (MDCT)
Number of subjects: 60
Study 26332107 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG‐gated 128‐DSCT
Number of subjects: 60
Study 26332107 — intervention group
Group type: EXPERIMENTAL
Intervention: Nongated 128‐DSCT
Number of subjects: 60
Study 26332107 — intervention group
Group type: COMPARATOR
Intervention: Control group (ECG‐gated 64‐slice MDCT)
Number of subjects: 60
Study 24417710 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm of three physician billing codes (separated by at least 30 days) in 2 years or one hospitalization
Number of subjects: 7500
Study 22237311 — intervention group
Group type: EXPERIMENTAL
Intervention: SB-649868 10 mg
Number of subjects: 51